Balance Sheet
Accounts PayablesAccumulated DepreciationAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fortress Biotech (FBIO) Receivables (2016 - 2025)

Fortress Biotech has reported Receivables over the past 11 years, most recently at $29.8 million for Q4 2025.

  • Quarterly results put Receivables at $29.8 million for Q4 2025, up 191.11% from a year ago — trailing twelve months through Dec 2025 was $29.8 million (up 191.11% YoY), and the annual figure for FY2025 was $29.8 million, up 191.11%.
  • Receivables for Q4 2025 was $29.8 million at Fortress Biotech, up from $18.0 million in the prior quarter.
  • Over the last five years, Receivables for FBIO hit a ceiling of $31.8 million in Q3 2021 and a floor of $8.0 million in Q3 2023.
  • Median Receivables over the past 5 years was $19.8 million (2021), compared with a mean of $20.7 million.
  • Biggest five-year swings in Receivables: surged 265.43% in 2021 and later plummeted 72.0% in 2023.
  • Fortress Biotech's Receivables stood at $23.7 million in 2021, then grew by 20.65% to $28.6 million in 2022, then crashed by 46.44% to $15.3 million in 2023, then crashed by 33.23% to $10.2 million in 2024, then skyrocketed by 191.11% to $29.8 million in 2025.
  • The last three reported values for Receivables were $29.8 million (Q4 2025), $18.0 million (Q3 2025), and $15.6 million (Q2 2025) per Business Quant data.